Meridian Bioscience this week reported that its fiscal first-quarter revenues increased 8 percent due in part to strong sales of its Illumigene isothermal amplification-based molecular diagnostic tests.

In addition, the company said that it would continue in the near term to focus on building out its Illumigene franchise, and that it expects to launch three to four new tests based on the technology each year for the foreseeable future.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.